Science News
from research organizations

Novel Mouse Model Of Osteosarcoma Developed

Date:
June 14, 2008
Source:
Cold Spring Harbor Laboratory
Summary:
A new mouse model of osteosarcoma has been developed. Osteosarcoma is the most common type of malignant bone cancer, and one of the most lethal: The 5-year survival rate is only about 60%, and this statistic drops steeply once the cancer spreads.
Share:
       
FULL STORY

In the June 15th issue of Genes & Development, Dr. Stuart Orkin (HHMI, Dana-Farber Cancer Institute, Children's Hospital Boston) and colleagues present a new mouse model of osteosarcoma.

Osteosarcoma is the most common type of malignant bone cancer, and one of the most lethal: The 5-year survival rate is only about 60%, and this statistic drops steeply once the cancer spreads. Osteosarcoma results from the dysregulated growth of osteoblasts (the cells that form the bone matrix). It primarily develops near the ends of the femur, tibia or humerus, and is usually diagnosed during adolescence, when the long bones of the body are undergoing rapid growth.

While the precise causes of osteosarcoma are unknown, it is evident that two tumor suppressor genes -- p53 and Rb -- are involved, as children with familial mutation syndromes affecting either of these genes have higher incidences of osteosarcoma.

Dr. Orkin's team has developed a novel experimental system to model the genetics of human osteosarcoma. The researchers generated a strain of transgenic mice lacking specifically the p53 and Rb genes in an early osteoblast progenitor cell population. All mutant animals rapidly developed osteosarcomas, with clinical, histo-cytological and molecular features closely recapitulating the human disease.

The scientists concluded that p53 loss is essential for the development of osteosarcoma, and that while Rb gene mutation acts synergistically with p53 loss to facilitate carcinogenesis, loss of Rb, alone, is not sufficient to induce osteosarcomagenesis.

Ultimately, this high-fidelity animal model will further elucidate the genetic contributions to osteosarcoma, and enable researchers to rationally design and test new therapies. Dr. Orkin is hopeful that "our work will stimulate translational efforts to develop novel therapies for this devastating bone tumor".


Story Source:

The above post is reprinted from materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Cite This Page:

Cold Spring Harbor Laboratory. "Novel Mouse Model Of Osteosarcoma Developed." ScienceDaily. ScienceDaily, 14 June 2008. <www.sciencedaily.com/releases/2008/06/080614170515.htm>.
Cold Spring Harbor Laboratory. (2008, June 14). Novel Mouse Model Of Osteosarcoma Developed. ScienceDaily. Retrieved July 28, 2015 from www.sciencedaily.com/releases/2008/06/080614170515.htm
Cold Spring Harbor Laboratory. "Novel Mouse Model Of Osteosarcoma Developed." ScienceDaily. www.sciencedaily.com/releases/2008/06/080614170515.htm (accessed July 28, 2015).

Share This Page: